Bristol-Myers Squibb's deucravacitinib – one of the main pipeline assets in its $74 billion takeover of Celgene in 2019 – has been approved in its first market as a treatment for moderate-to-severe ...

Bristol-Myers Squibb’s KRAS inhibitor Krazati has been approved for a second indication, colorectal cancer (CRC), which could inject some much-needed sales growth into the product. The FDA has given ...

Transform Your Shoes into Electric Roller Skates at Home! Discover how to create your own electric roller skate shoes with our step-by-step tutorial! Equip yourself with 20 DC motors with wheels, ...